

**SINGAPORE MEDICAL GROUP LIMITED**  
(Company Registration No.: 200503187W)

---

**USE OF PROCEEDS FROM THE RIGHTS ISSUE**

---

*All capital terms used and not defined herein shall have the same meanings given to them in the Offer Information Statement (the “OIS”) dated 18 June 2018, unless otherwise expressly stated or the context otherwise requires.*

Further to the announcements made on 23 October 2018, 1 November 2018 and 5 November 2018, the Board of Directors (the “**Board**”) of Singapore Medical Group Limited (the “**Company**”), and together with its subsidiaries, the “**Group**”) would like to provide an update on the use of the net proceeds from the Rights Issue as follows:

<u>Use of Net Proceeds</u>	Allocation of Net Proceeds	Net Proceeds utilised as at 5 November 2018	Net Proceeds	Balance of
			utilised from 5 November 2018 to 10 December 2018	Net Proceeds as at 10 December 2018
	S\$ million	S\$ million	S\$ million	S\$ million
(i) Merger and acquisitions	4.6	(1.4)	-	3.2
(ii) Growing existing business	2.0	(0.4)	(0.4)	1.2
	6.6	(1.8)	(0.4)	4.4

The above use of proceeds for growing existing business of S\$0.4 million is in relation to the purchase of medical equipment and renovation.

The above use of proceeds is in accordance with the intended use as stated in the OIS dated 18 June 2018 in relation to the Rights Issue.

The Company will continue to make periodic announcements via SGXNET upon utilisation of the remaining Rights Issue Proceeds as and when the funds are materially disbursed.

**By Order of the Board**

Dr Beng Teck Liang  
Executive Director and Chief Executive Officer  
10 December 2018

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, CIMB Bank Berhad, Singapore Branch (the “Sponsor”), for compliance with the relevant rules of the SGX-ST, this being the SGX-ST Listing Manual Section B: Rules of Catalyst. The Sponsor has not independently verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Eric Wong, Director, Investment Banking, Singapore. The contact particulars are 50 Raffles Place, #09-01 Singapore Land Tower, Singapore 048623, Telephone: +65 6337 5115.*